Regulatory/Legislative News

In my original blog on this theme, I discussed the expanded role of optometry in the management of patients with diabetes. For any optometrist who is practicing in the “medical model,” this is an urgent public health need and a large opportunity to expand your practice.

The FDA has granted 510(k) clearance for the SMD-Sr90-DA Radionuclide Brachytherapy Source, according to a press release from Salutaris Medical Devices.

The FDA has designated miltefosine as an orphan drug for the treatment of Acanthamoeba keratitis, according to a press release from Profounda.

A registration application for Oxervate eye drops for the treatment of moderate and severe neurotrophic keratitis in adults has been accepted by the European Medicines Agency, according to a Dompé press release.

Many pharmaceutical stock prices dropped today after President-elect Donald Trump announced in an interview with Time magazine that he will attempt to bring down drug prices during his presidential term.

The shift to a Trump administration could mean several health insurance changes and the strengthening of Medicaid.

The FDA has granted 510(k) clearance for the Navilas Laser System 577s, a compact, all-digital system for navigated focal and peripheral laser treatments, making it immediately available in the U.S., according to correspondence from OD-OS, the system’s manufacturer.

This month marks a turning point in American history. No matter what political position you may have held prior to the election, you will need to reevaluate your thoughts and ideas as we all face a new reality.

The FDA has cleared Allergan’s Xen glaucoma treatment system for refractory glaucoma, according to a company press release.

The FDA has cleared the PLEX Elite 9000 for advanced retina research, Carl Zeiss Meditec announced in a press release.